Market Overview

Myasthenia Gravis - Pipeline Insight, 2018 Report -


The "Myasthenia
Gravis - Pipeline Insight, 2018"
drug pipelines has been added
to's offering.

'Myasthenia Gravis - Pipeline Insight, 2018' report offers comprehensive
Insight of the pipeline (under development) therapeutics scenario and
growth prospects across Myasthenia Gravis development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Myasthenia Gravis Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

  • Achillion Pharmaceuticals Inc
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals Inc
  • ArGEN-X BV
  • CuraVac Inc
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co Ltd
  • Karus Therapeutics Ltd
  • Millennium Pharmaceuticals Inc
  • Neurotune AG
  • Novartis AG

For more information about this drug pipelines report visit

View Comments and Join the Discussion!